Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.7K
Overview
51.7K
Recombinant DNA01:09

Recombinant DNA

103.3K
Overview
103.3K
Homologous Recombination02:31

Homologous Recombination

63.2K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
63.2K
Homologous Recombination02:31

Homologous Recombination

6.6K
6.6K
Viral Recombination00:57

Viral Recombination

25.2K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.2K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.8K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation and characterization of emerging Mpox virus from India.

Journal of medical virology·2023
Same author

Development and evaluation of indirect antibody ELISA assay for early diagnosis and surveillance of Crimean-Congo hemorrhagic fever infection in humans.

Virus research·2022
Same author

Development of double antibody sandwich ELISA as potential diagnostic tool for rapid detection of Crimean-Congo hemorrhagic fever virus.

Scientific reports·2021
Same author

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development.

Frontiers in bioengineering and biotechnology·2020
Same author

Development of Multispecies Recombinant Nucleoprotein-Based Indirect ELISA for High-Throughput Screening of Crimean-Congo Hemorrhagic Fever Virus-Specific Antibodies.

Frontiers in microbiology·2019
Same author

Evaluation of antibody response against recombinant domain III proteins of dengue virus type 1 and 2.

AIMS microbiology·2019

Related Experiment Video

Updated: Feb 5, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.4K

Recent Developments in Recombinant Protein-Based Dengue Vaccines.

Nagesh K Tripathi1, Ambuj Shrivastava2

  • 1Bioprocess Scale Up Facility, Defence Research and Development Establishment, Gwalior, India.

Frontiers in Immunology
|September 8, 2018
PubMed
Summary

Developing recombinant protein vaccines is crucial for dengue prevention, as current options offer limited protection. Research focuses on novel immunogens and adjuvants for more effective dengue vaccines.

Keywords:
chimeric vaccinedengue virusrecombinant proteintetravalent vaccinevaccine

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.4K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Area of Science:

  • Biotechnology
  • Vaccinology
  • Virology

Background:

  • Dengue virus poses a global health threat, with no specific antiviral therapy available, making prevention through vaccination essential.
  • The existing dengue vaccine (Dengvaxia) has limitations in providing balanced protection across all four serotypes.
  • Recombinant proteins are increasingly important for biopharmaceutical products due to their safety and efficacy.

Purpose of the Study:

  • To review recent advancements in recombinant protein-based dengue vaccines.
  • To highlight strategies for developing novel and improved dengue vaccine candidates.
  • To discuss the potential of recombinant proteins in creating cost-effective, large-scale vaccine solutions.

Main Methods:

  • Exploration of various dengue vaccine development approaches, including recombinant subunit vaccines.
  • Production of dengue virus proteins (envelope and non-structural) in different host systems.
  • Design of novel immunogens through protein engineering and fusion with immunostimulatory motifs.

Main Results:

  • Recombinant subunit vaccines, particularly those based on envelope or non-structural proteins, show promise.
  • Engineered immunogens and novel adjuvant formulations enhance vaccine immunogenicity and protection.
  • Advancements in host systems enable cost-effective, large-scale production of recombinant proteins for vaccine studies.

Conclusions:

  • Recombinant protein-based vaccines represent a significant strategy for developing efficacious dengue vaccines.
  • Further research into novel immunogens and formulation strategies can lead to improved dengue vaccine candidates.
  • These advancements offer hope for alternative dengue vaccine options to combat the global disease burden.